<p>Blair William &amp; Co. IL 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在 Dynavax Technologies Co.（NASDAQ:DVAX - 免费报告）的持股减少了 3.8%。该机构投资者在本季度出售了 89,031 股后，持有生物制药公司 2,261,677 股股票。Blair William &amp; Co. IL 在最近的报告期末持有的 Dynavax Technologies 的股份约占 1.72%，价值 28,882,000 美元。</p>
<p>获取 <strong>Dynavax Technologies</strong> 警报：</p>
<p>其他一些对冲基金和机构投资者也买卖了该公司的股票。PDT Partners LLC 在第三季度购买了 Dynavax Technologies 的新股份，价值约为 3,967,000 美元。WINTON GROUP Ltd 在第四季度将其在 Dynavax Technologies 的持股增加了 339.0%。WINTON GROUP Ltd 现在拥有 426,814 股生物制药公司的股票，价值 5,450,000 美元，此前在上个季度又收购了 329,579 股。Nordea Investment Management AB 在第四季度将其在 Dynavax Technologies 的持股增加了 42.7%。Nordea Investment Management AB 现在拥有 777,816 股生物制药公司的股票，价值 10,034,000 美元，此前在该期间又收购了 232,690 股。Barclays PLC 在第三季度将其在 Dynavax Technologies 的股份增加了 137.4%。Barclays PLC 现在拥有 302,572 股生物制药公司的股票，价值 3,371,000 美元，此前在上个季度又收购了 175,118 股。最后，加拿大蒙特利尔银行在第三季度将其在 Dynavax Technologies 的持股增加了 8.3%。加拿大蒙特利尔银行现在拥有 1,077,081 股生物制药公司的股票，价值 11,848,000 美元，此前在该期间又购买了 82,449 股。机构投资者持有该公司 96.96% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>DVAX 最近成为多份研究报告的主题。高盛集团将 Dynavax Technologies 的评级从 “中性” 下调至 “卖出”，并在 2 月 11 日的报告中将其目标价从 15.00 美元下调至 12.00 美元。StockNews.com 在 2 月 24 日的研究报告中将 Dynavax Technologies 的评级从 “持有” 上调至 “买入”。William Blair 在 2 月 21 日的研究报告中重申了对 Dynavax Technologies 的 “跑赢大盘” 评级。最后，HC Wainwright 在 2 月 21 日的研究报告中重新发布了 “买入” 评级，并设定了 31.00 美元的目标价。</p>
<p><strong>查看我们关于 DVAX 的最新报告</strong></p>
<h2>Dynavax Technologies 股票上涨 1.0%</h2>
<p>Dynavax Technologies 股票在周五开盘价为 13.72 美元。该股票的 50 日移动平均线为 13.32 美元，200 日移动平均线为 12.47 美元。Dynavax Technologies Co. 的一年低点为 9.74 美元，一年高点为 14.63 美元。该公司的市值为 17 亿美元，市盈率为 76.22，贝塔值为 1.23。该公司的债务与股本比率为 0.33，流动比率为 13.23，速动比率为 12.34。</p>
<p>Dynavax Technologies（NASDAQ:DVAX - 获取免费报告）最近在 2 月 20 日宣布了其季度收益数据。该生物制药公司报告本季度每股收益为 0.05 美元，符合市场共识预期的 0.05 美元。Dynavax Technologies 的净利润率为 9.85%，股本回报率为 4.22%。该公司在本季度的收入为 7203 万美元，而市场共识预期为 7270 万美元。股票研究分析师预计 Dynavax Technologies Co. 在当前年度将发布 0.32 美元的每股收益。</p>
<h2>Dynavax Technologies 公司简介</h2>
<p>（免费报告）</p>
<p>Dynavax Technologies Corporation 是一家商业阶段的生物制药公司，专注于在美国开发和商业化疫苗。它在美国和欧洲市场销售 HEPLISAV-B，这是一种用于预防所有已知亚型的乙型肝炎病毒感染的乙型肝炎疫苗，适用于 18 岁及以上人群。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Dynavax Technologies</li>
<li>最具波动性的股票，投资者需要了解的事项</li>
<li>便士股票激增，Pays 上涨 70%：买入的一个理由，卖出的五个理由</li>
<li>深入了解买卖差价</li>
<li>三大饮料股票带来丰厚利润</li>
<li>投资旅游股票的好处</li>
<li>CarMax 和 Carvana：引领二手车市场</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Dynavax Technologies 吗？</h2>
<p>在你考虑 Dynavax Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Dynavax Technologies 并不在名单上。</p>
<p>虽然 Dynavax Technologies 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

德纳维制药

<p>Blair William & Co. IL 在第四季度减少了对 Dynavax Technologies Co.（NASDAQ:DVAX）的持股比例，下降了 3.8%，目前持有 2,261,677 股，价值约为 2888 万美元。其他机构投资者也调整了他们的持仓，PDT Partners LLC 新增了持股，而 WINTON GROUP Ltd 的持股增加了 339%。分析师对 DVAX 的评级不一，高盛将其评级下调至 “卖出”，而 HC Wainwright 维持 “买入” 评级，目标价为 31.00 美元。Dynavax 报告上个季度的收入为 7203 万美元，符合预期</p>

<p>Blair William &amp; Co. IL decreased its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 3.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 2,261,677 shares of the biopharmaceutical company's stock after selling 89,031 shares during the quarter. Blair William &amp; Co. IL owned approximately 1.72% of Dynavax Technologies worth $28,882,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Blair William &amp; Co. IL 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在 Dynavax Technologies Co.（NASDAQ:DVAX - 免费报告）的持股减少了 3.8%。该机构投资者在本季度出售了 89,031 股后，持有生物制药公司 2,261,677 股股票。Blair William &amp; Co. IL 在最近的报告期末持有的 Dynavax Technologies 的股份约占 1.72%，价值 28,882,000 美元。</p>
</div><p>Get <strong>Dynavax Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Dynavax Technologies</strong> 警报：</p>
</div><p>A number of other hedge funds and other institutional investors have also bought and sold shares of the company. PDT Partners LLC bought a new stake in shares of Dynavax Technologies during the third quarter worth about $3,967,000. WINTON GROUP Ltd grew its holdings in Dynavax Technologies by 339.0% during the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company's stock worth $5,450,000 after acquiring an additional 329,579 shares during the last quarter. Nordea Investment Management AB increased its position in Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company's stock valued at $10,034,000 after acquiring an additional 232,690 shares during the period. Barclays PLC raised its stake in shares of Dynavax Technologies by 137.4% during the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock valued at $3,371,000 after acquiring an additional 175,118 shares during the last quarter. Finally, Bank of Montreal Can lifted its holdings in shares of Dynavax Technologies by 8.3% during the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock worth $11,848,000 after purchasing an additional 82,449 shares during the period. Institutional investors own 96.96% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者也买卖了该公司的股票。PDT Partners LLC 在第三季度购买了 Dynavax Technologies 的新股份，价值约为 3,967,000 美元。WINTON GROUP Ltd 在第四季度将其在 Dynavax Technologies 的持股增加了 339.0%。WINTON GROUP Ltd 现在拥有 426,814 股生物制药公司的股票，价值 5,450,000 美元，此前在上个季度又收购了 329,579 股。Nordea Investment Management AB 在第四季度将其在 Dynavax Technologies 的持股增加了 42.7%。Nordea Investment Management AB 现在拥有 777,816 股生物制药公司的股票，价值 10,034,000 美元，此前在该期间又收购了 232,690 股。Barclays PLC 在第三季度将其在 Dynavax Technologies 的股份增加了 137.4%。Barclays PLC 现在拥有 302,572 股生物制药公司的股票，价值 3,371,000 美元，此前在上个季度又收购了 175,118 股。最后，加拿大蒙特利尔银行在第三季度将其在 Dynavax Technologies 的持股增加了 8.3%。加拿大蒙特利尔银行现在拥有 1,077,081 股生物制药公司的股票，价值 11,848,000 美元，此前在该期间又购买了 82,449 股。机构投资者持有该公司 96.96% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>DVAX has been the subject of a number of recent research reports. The Goldman Sachs Group downgraded Dynavax Technologies from a &#34;neutral&#34; rating to a &#34;sell&#34; rating and decreased their price objective for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. StockNews.com raised Dynavax Technologies from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Monday, February 24th. William Blair reaffirmed an &#34;outperform&#34; rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, HC Wainwright reissued a &#34;buy&#34; rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st.</p>
<div class="lb-trans"><p>DVAX 最近成为多份研究报告的主题。高盛集团将 Dynavax Technologies 的评级从 “中性” 下调至 “卖出”，并在 2 月 11 日的报告中将其目标价从 15.00 美元下调至 12.00 美元。StockNews.com 在 2 月 24 日的研究报告中将 Dynavax Technologies 的评级从 “持有” 上调至 “买入”。William Blair 在 2 月 21 日的研究报告中重申了对 Dynavax Technologies 的 “跑赢大盘” 评级。最后，HC Wainwright 在 2 月 21 日的研究报告中重新发布了 “买入” 评级，并设定了 31.00 美元的目标价。</p>
</div><p><strong>View Our Latest Report on DVAX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 DVAX 的最新报告</strong></p>
</div><h2>Dynavax Technologies Stock Up 1.0 %</h2>
<div class="lb-trans"><h2>Dynavax Technologies 股票上涨 1.0%</h2>
</div><p>Shares of Dynavax Technologies stock opened at $13.72 on Friday. The stock's 50-day moving average is $13.32 and its 200 day moving average is $12.47. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $14.63. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of 76.22 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.</p>
<div class="lb-trans"><p>Dynavax Technologies 股票在周五开盘价为 13.72 美元。该股票的 50 日移动平均线为 13.32 美元，200 日移动平均线为 12.47 美元。Dynavax Technologies Co. 的一年低点为 9.74 美元，一年高点为 14.63 美元。该公司的市值为 17 亿美元，市盈率为 76.22，贝塔值为 1.23。该公司的债务与股本比率为 0.33，流动比率为 13.23，速动比率为 12.34。</p>
</div><p>Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Equities research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.</p>
<div class="lb-trans"><p>Dynavax Technologies（NASDAQ:DVAX - 获取免费报告）最近在 2 月 20 日宣布了其季度收益数据。该生物制药公司报告本季度每股收益为 0.05 美元，符合市场共识预期的 0.05 美元。Dynavax Technologies 的净利润率为 9.85%，股本回报率为 4.22%。该公司在本季度的收入为 7203 万美元，而市场共识预期为 7270 万美元。股票研究分析师预计 Dynavax Technologies Co. 在当前年度将发布 0.32 美元的每股收益。</p>
</div><h2>Dynavax Technologies Company Profile</h2>
<div class="lb-trans"><h2>Dynavax Technologies 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.</p>
<div class="lb-trans"><p>Dynavax Technologies Corporation 是一家商业阶段的生物制药公司，专注于在美国开发和商业化疫苗。它在美国和欧洲市场销售 HEPLISAV-B，这是一种用于预防所有已知亚型的乙型肝炎病毒感染的乙型肝炎疫苗，适用于 18 岁及以上人群。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Dynavax Technologies</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Top 3 Beverage Stocks Pouring Out Profits</li>
<li>Investing in Travel Stocks Benefits</li>
<li>CarMax and Carvana: Steering the Used Car Market</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Dynavax Technologies</li>
<li>最具波动性的股票，投资者需要了解的事项</li>
<li>便士股票激增，Pays 上涨 70%：买入的一个理由，卖出的五个理由</li>
<li>深入了解买卖差价</li>
<li>三大饮料股票带来丰厚利润</li>
<li>投资旅游股票的好处</li>
<li>CarMax 和 Carvana：引领二手车市场</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=DVAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Dynavax Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Dynavax Technologies 吗？</h2>
</div><p>Before you consider Dynavax Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Dynavax Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Dynavax Technologies 并不在名单上。</p>
</div><p>While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dynavax Technologies 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Blair William & Co. IL 在德纳维制药公司（NASDAQ:DVAX）持有价值 2888 万美元的股份